Full Text View
Tabular View
No Study Results Posted
Related Studies
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
This study has been completed.
Study NCT00072943   Information provided by Facet Biotech

First Received on November 12, 2003.   Last Updated on March 9, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Crohn's Disease
Colitis
Intestinal Disease
Gastrointestinal Disease
Digestive System Disease
Additional conditions recognized in this trial
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
More general conditions related to this trial
Colonic Diseases
Gastroenteritis
Inflammatory Bowel Diseases
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Interferon-gamma
Interferons
More general drug interventions related to this trial
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Facet Biotech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services